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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Objectives: To evaluate the long-term surgical, functional, and quality-of-life (QoL) ou-
tcomes after Holmium laser enucleation of the prostate (HoLEP) in patients with sympto-
matic benign prostatic hyperplasia (BPH).
Materials and Methods: We retrospectively reviewed recorded data on patients who un-
derwent HoLEP between June 2002 and February 2005. Ninety-six patients were enrol-
led. Demographic, perioperative, and postoperative data were recorded. On follow-up, 
International Prostate Symptom Scores (IPSSs), prostate-specific antigen (PSA) levels, 
QoL scores, peak uroflowmetric data (Qmax values), and post-voiding residual urine volu-
mes (PVR volumes), were recorded. Complications were scored using the Clavien system. 
Statistical significance was set at p<0.05.
Results: The mean follow-up time was 41.8±34.6 months and the mean patient age 
73.2±8.7 years. The mean prostate volume was 74.6±34.3mL. Significant improve-
ments in Qmax values, QoL, and IPSSs and decreases in PSA levels and PVR volumes 
were noted during follow-up (all p values=0.001). The most common complication 
was a requirement for re-catheterisation because of urinary retention. Two patients 
had concomitant bladder tumours that did not invade the muscles. Eight patients 
(8.3%) required re-operations; three had residual adenoma, three urethral strictures, 
and two residual prostate tissue in the bladder. Stress incontinence occurred in one 
patient (1%). All complications were of Clavien Grade 3a. We noted no Clavien 3b, 4, 
or 5 complications during follow-up.
Conclusions: HoLEP improved IPSSs, Qmax values, PVR volumes, and QoL and was asso-
ciated with a low complication rate, during extended follow-up. Thus, HoLEP can be a 
viable option to transurethral resection of the prostate.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is 
common in elderly males (1). Medical treatment 
is usually the first choice (2). If this is inadequa-
te, surgery may be required (3). Transurethral re-
section of the prostate (TURP) has long been the 
accepted gold standard to treat symptomatic di-
sease of prostates weighing 30-80g (3). Open pros-
tatectomy may be used to treat larger prostates 
Vol. 42 (2): 293-301, March - April, 2016
doi: 10.1590/S1677-5538.IBJU.2014.0561
ibju | HigH QoL for HoLEP in ExtEndEd foLLow-uP              
294
(3). However, TURP may cause TURP syndrome, 
and open surgery may trigger gross bleeding, de-
layed recovery, and a decrease in the quality-of-
-life (QoL). Efforts to develop minimally invasive 
surgeries are continuing. Laser therapy afforded 
a quantum jump in such efforts; laser-mediated 
prostate enucleation is now commonplace (3) and 
has recently been accepted as an alternative treat-
ment for BPH (4). Specifically, holmium laser enu-
cleation of the prostate (HoLEP) is used to treat 
enlarged prostates, particularly in patients taking 
anticoagulants (5). HoLEP is safe and the compli-
cation rate acceptable (6); HoLEP afforded very 
good results when used to treat symptomatic BPH 
(4-6). Many relevant publications have appeared 
(7). However, although several studies featured 
3-10 years of follow-up, longer-term follow-up 
data are lacking.
Herein, we evaluated the long-term sur-
gical and functional results obtained by HoLEP, 
in patients with symptomatic BPH. Additionally, 
complications and QoL were evaluated. To the best 
of our knowledge, this is first study to evaluate 
QoL as an outcome during extended follow-up.
MATERIALS AND METHODS
We retrospectively evaluated prospective 
data recorded by two surgeons (I.A. and Y.A.). All 
patients gave written informed consent and the 
Institutional Review Board approved the study. A 
total of 114 patients underwent HoLEP between 
June 2002 and February 2005. Exclusion crite-
ria were the absence of follow-up data, previous 
prostate surgery, prostate cancer (PCa), and/or a 
neurological disease. If a suspicious prostate no-
dule was evident upon digital rectal examination 
(DRE), and/or the prostate specific antigen (PSA) 
level was elevated (>4ng/mL), prostate biopsy 
guided by transrectal ultrasonography was perfor-
med. Patients with PCa, developed either before 
or after HoLEP, were excluded. All patients were 
continent prior to operation. Finally, 96 patients 
were enrolled.
Patient Data
Demographic data included age (in years), 
previous operations, co-morbidities, and medica-
tions taken. Preoperative data included prosta-
te volume; uroflowmetric parameters including 
the maximum flow rate (Qmax); post-voiding re-
sidual urine volume (PVR volume; mL), score on 
the Turkish version of the International Prostate 
Symptom Score (IPSS) (8); serum PSA level (ng/
dL), DRE findings, and QoL questionnaire respon-
ses. Perioperative data included operation time; 
enucleation time; morcellation time; and the wei-
ght of enucleated tissue. Postoperative data con-
sisted of hospital stay (days); duration of urethral 
catheterisation; pathology findings; and compli-
cations evaluated using the Clavien-Dindo system 
(9). To assess QoL, we used the World Health Orga-
nization Quality of Life Scale (Brief Version). QoL 
questionnaires were completed both before opera-
tion and during the follow-up period.
The operation
Gilling et al. have described the HoLEP pro-
cedure (10). All operations were performed using a 
100W Ho: Yag laser fitted with a 550µm end-firing 
fibre (LumenisⓇ, Santa Clara, CA, USA) and 25.6-or 
27-Fr continuous-flow resectoscopes with modified 
working elements (25.6 Fr: ACMIⓇ, Southborough, 
MA, USA; 27 Fr: Olympus, Hamburg, Germany). The 
laser fibre was stabilised within a 6-Fr ureteral ca-
theter and inserted into the channel of the modified 
working element. A 26-Fr nephroscope (StorzⓇ, Tut-
tlingen, Germany) was used for morcellation. All pro-
cedures were performed under regional anaesthesia.
Briefly, the urethra was calibrated to 30Fr 
and the resectoscope inserted (after positioning) in 
the operating theatre. Room-temperature saline was 
used for irrigation. The preferred laser settings were 
2J at 50Hz, or 2J at 40Hz. Initially, two incisions 
were performed at the 5 and 7 o’clock positions, late-
ral to the median lobe, from the neck of the bladder 
to the verumontanum, using the 550µm laser fibre. 
The distal ends of the incisions were joined just be-
fore the level of the verumontanum, and retrogra-
de cutting continued to the neck of the bladder, to 
enucleate the median lobe (Figure- 1A). The inci-
sion was then extended upward, beneath the lateral 
lobe, to the 7 o’clock level of the verumontanum. 
Another incision was created from the neck of the 
bladder to the 12 o’clock position of the verumon-
tanum, enucleating the left lateral lobe (Figure-1B). 
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The incisions were joined just before the level of the 
verumontanum, and cutting continued retrograde to 
the bladder neck, to complete enucleation of the la-
teral lobe (Figure-1C). The same technique was used 
to enucleate the right lobe. Next, the prostatic fossa 
was checked for bleeding, and any necessary coa-
gulation performed using a laser beam delivering 2J 
at 40Hz. A Versacut tissue morcellator (LumenisⓇ) 
was used to remove enucleated prostate tissue from 
the bladder. A specifically designed laser resectos-
cope fitted with a Morce-scope set (WolfⓇ, Knittin-
gen, Germany) were used to treat the last 20 cases 
(this equipment became commercially available 
only recently). Large lobes were removed from the 
bladder after morcellation. It is essential to ensure 
good vision and adequate bladder distention during 
morcellation, to prevent bladder wall entrapment by 
the morcellator blades (Figure-1D). At the end of the 
procedure, a 20-Fr two-way Foley catheter was in-
dwelled; this was removed 1 day later if haematuria 
was absent.
Follow-up
Follow-up was conducted at 1, 3, and 6 
months after operation, and yearly thereafter. IPSSs, 
uroflowmetric data, serum PSA level, PVR volume, 
QoL, and IIEF data were evaluated.
Continence status was investigated using the 
short form of the International Continence Society. 
Incontinence was defined as a need for more than 
one protective pad daily (11). Complete dryness or 
the need for less than one pad daily was accepted 
as continence. If an erection adequate to engage 
in sexual intercourse was attained, with or without 
medication, the patient was considered potent. All 
patients completed International Index of Erectile 
Figure-1 - Enucleation and morcellation were performed respectively during operation. A) Incisions were performed from 
bladder neck to verumontanum level in terms of enucleating prostate lobes. Black arrow shows laser probe and white arrow 
shows bladder neck, B) An incision was performed from the bladder neck to the verumontanum level at 12 o’clock position, 
black arrow shows laser probe, C) Incisions were continued to the bladder neck and lateral lobe enucleation was completed; 
black arrow shows laser probe, D) Then, morcellation was performed; black arrow shows the tip of morcellator.
A
C D
B
ibju | HigH QoL for HoLEP in ExtEndEd foLLow-uP              
296
Function (IIEF) questionnaires before and after Ho-
LEP. If the IIEF-5 score of a patient was≤11, that pa-
tient was considered to exhibit erectile dysfunction. 
Continence and erectile status were assessed every 
year during follow-up. However, both surgeons 
changed their workplace, and the vast majority of 
patients were lost to follow-up at 6 and 7 years.
Statistical analyses
The Statistical Package for the Social Scien-
ces (SPSS) for Windows, version 16.0 (SPSS Inc., 
Chicago, IL), was used for statistical analysis. The in-
dependent samples t-test was employed to compare 
continuous data, and one-way analysis of variance 
was also used for between-group comparisons. Sta-
tistical significance was set at p<0.05.
RESULTS
The mean follow-up time was 41.8±34.6 
months and the mean patient age 73.2±8.7 years. 
The mean prostate weight was 74.6±34.3g. Ninety 
patients (93.75%) were taking oral alpha-blockers 
to treat BPH. Additionally, 41 patients were taking 
the 5-alpha reductase inhibitor dutasteride. Demo-
graphic and preoperative data are summarised in 
Table-1.
The mean operation time was 97±42.2 min 
including a mean morcellation time of 17.8±15.1 
min. The mean weight of enucleated tissue was 
29.2±11.3g. The mean duration of catheterisation 
was 1.2±0.8 days and the mean hospital stay 1.1±0.4 
days (Table-2).
Significant improvements in all Qmax value, 
QoL, PVR volume, and IPSS were evident during 
follow-up (all p values=0.001). Also, Qmax and QoL 
improved further every subsequent year. Dramatic 
decreases in PVR volume and the IPSS occurred im-
mediately after operation. All improvements were 
maintained during extended follow-up. Additio-
nally, the mean postoperative PSA level decreased 
significantly from the preoperative value (p=0.001). 
The preoperative and postoperative erectile function 
index scores were similar (Table-3 and Figure-2).
The most common complication was a re-
quirement for re-catheterisation to treat urinary 
retention after removing the first catheter on day 
Table 1 - Demographic and perioperative data of study 
group.
Parameter Mean±SD
Age (years) 73.2±8.7
PSA (ng/dL) 4.5±0.3
IPSS 22.1±6.1
Qmax (mL/sec.) 10.8±4.8
Prostate volume (g) 74.6±34.3
PVR 219.8±220.9
QoL score 4.6±1.2
IPSS = International prostate symptom score; PSA = Prostate specific antigen; 
PVR = Post voiding residual urine volume; SD = Standard deviation; Qmax = 
Maximum flow rate in uroflowmetry; QoL = Quality of life.
Table 2 - Peri- and post-operative data.
Parameter Mean±SD
Operation time (min.) 97±42.2
Energy (kj) 206.8±131.96
Morcellation time (min.) 17.8±15.1
Volume of enucleated tissue (g) 29.2±11.3
Duration of catheter (day) 1.2±0.8
Hospital stay (day) 1.1±0.4
SD = Standard deviation.
1 after surgery (seven patients). Additional non-
-steroidal anti-inflammatory drugs were prescri-
bed, and catheters were re-inserted. We removed 
the catheters 2 days later. Eight patients (8.3%) re-
quired re-operations; three had residual adenoma, 
three urethral strictures, and two residual prostate 
tissue in the bladder (one because of morcellator 
malfunction and one because of a surgeon’s error). 
All complications were of Clavien Grade 3a. Stress 
urinary incontinence occurred in one patient 
(1%); this was a Clavien 2 complication. The pa-
tient refused surgical intervention. No Clavien 3b, 
4, or 5 complication developed during extended 
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Table 3 - Evaluation of param
eters in follow
-up period.
Param
eters
Preoperative 
(n=96)
1 m
onth 
after 
HoLEP 
(n=96)
3 m
onths 
after 
HoLEP 
(88)
6 m
onths 
after 
HoLEP 
(n=71)
1 year after 
HoLEP 
(n=61)
2 years 
after HoLEP 
(n=58)
3 years 
after 
HoLEP 
(n=46)
4 years 
after 
HoLEP 
(n=36)
5 years 
after 
HoLEP 
(n=31)
6 years 
after 
HoLEP 
(n=25)
7 years 
after 
HoLEP 
(n=21)
P value
M
ean Q
m
ax
10.8±4.8
22.9±10.8
26.1±8.5
26.1±8.5
24.7±5.5
24.9±5.3
24.9±4.2
23.9±3.4
24.1±31
22.6±3.4
21.7±2.8
0.001*
M
ean QoL
4.6±1.2
1.8±0.1
1.6
1.4±0.2
1.1
1.2±0.1
0.9
1±0.1
1
1.1±0.1
1.1±0.3
0.001*
M
ean IPSS
22.1±6.1
5.5±3.8
4.3±2.9
3.3±1.7
3.1±1.7
3±1.3
2.8±1.3
2.6±1.2
2.7±1
2.5±1.1
2.6±0.9
0.001*
M
ean PVR
219.8±220.9
44.6±30
33.2±18.6
27.7±15
26.1±13.4
24.8±12.7
24.6±11.1
23.6±11.3
21.4±12.1
22.4±12.1
22±13.7
0.001*
M
ean PSA
4.5±0.3
N.A.
1.2±0.1
N.A.
1.1±0.1
1.2±0.1
1.2±0.1
1.2±0.1
1.1±0.1
1±0.1
1±0.1
0.001*
IIEF
16.5±6
16±5.4
15.5±5.5
17±5.4
17±5.3
17.5±5.4
17.5±4.9
17.5±5
18±4.3
18.5±4.4
18±4.1
0.2
IIEF =  International index of erectile function; IPSS = International Prostate sym
ptom
 score ; N.A = Not assessed; PSA = Prostate specific antigen; PVR = Post voiding residual urine volum
e; Q
m
ax  = M
axim
um
 flow rate in 
uroflowm
etry; QoL = Quality of life; PSA = Prostate specific antigen.
*Statistical significant P value, Independent t tests and One way ANOVA tests were used.
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Figure-2 - Graphics of parameters in long-term follow-up. A) Maximum flow rate in uroflowmetry, B) Quality of life, C) 
International Prostate symptom score, D) Post voiding residual urine volume, E) Prostate specific antigen, F) International 
index of erectile function, HoLEP: Holmium laser enucleation of the prostate.
follow-up. Two patients had concomitant bladder 
tumours that had not invaded the muscles, and 
these were successfully resected during HoLEP. 
One tumour had just begun to infiltrate the lamina 
propria. These two patients were followed-up in 
the urology outpatient clinic. Six patients (6.25%) 
had bladder stones, which were laser-fragmented 
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and removed. One patient required blood transfu-
sion; this was a Clavien 2 complication. The two 
patients who were on anticoagulants were allowed 
to continue their medication. In two instances, the 
bladder mucosa was injured by the morcellation 
device. Coagulation of the bladder mucosa was 
achieved using the holmium laser.
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Long-term erectile function was not affec-
ted by HoLEP; preoperative functionality neither 
increased nor decreased.
DISCUSSION
Benign prostatic obstruction caused by 
BPH is one of the most common health proble-
ms in elderly males (12), the proportions of whom 
are increasing, notably in industrialised countries 
(13). Therefore, urologists will see more males with 
BPH in the future. Surgical interventions must be 
canvassed when medical treatments such as al-
pha-blockers and/or 5-alpha reductase inhibitors 
fail (3). Understandably, BPH patients favour mi-
nimally invasive surgical options (14). HoLEP is 
an acceptable option in BPH patients with indi-
cations for surgery (15). However, few long-term 
follow-up data are available. We focused on long-
-term surgical and functional results, including 
QoL. This is the first HoLEP study with extended 
follow-up from Turkey.
The present series demonstrated statis-
tically significant improvements in Qmax values, 
QoL, and IPSS; and decreases in PSA levels and 
PVR volumes in extended follow-up. All of these 
scores are presented in Table-3. Mean Qmax was 
22.9mL/s one month after HoLEP. Naspro et al. 
reported similar results; the mean Qmax value was 
21.4mL/s after surgery (16). Yin et al. reported a 
significant improvement in IPSS after HoLEP (4). 
Krambeck et al. reported an increase in Qmax va-
lue (to a mean of 22.7mL/s) after HoLEP (17). QoL 
scores improved soon after HoLEP and continued 
to rise during extended follow-up. We found that 
QoL scores improved more than 2 times when 
compared to pre-operative period, one month af-
ter surgery. Sun et al. reported that QoL impro-
ved after HoLEP, being significantly better than 
after TURP (18). Our results are similar to those 
of the studies summarised above (4, 16-18). These 
are some of the primary end-points of our study 
which showed long-term effectivity of HoLEP. The 
fall in PSA level may be associated with prostate 
debulking (16).
Functional results reflected another benefit 
of HoLEP. Sexual functioning was neither assisted 
nor worsened by HoLEP. Klett et al. found that 
HoLEP did not adversely affect sexual function in 
the long-term (19). Jeong et al. reported a slight 
decrease in sexual functioning after operation, but 
this had improved 12 months later (20). However, 
the probability of retrograde ejaculation is 75% 
after operation (21). Our findings were similar with 
these studies (19-21). The HoLEP procedure helped 
to preserve sexual functions, but retrograde eja-
culation still remains a problem. Improvements in 
voiding and sexual activity caused QoL scores to 
rise. Elmansy et al. reported long-term follow-up 
data after HoLEP (22). However, although good 
surgical and functional results were noted, QoL 
was not addressed. We have shown here that QoL 
improved upon long-term follow-up after HoLEP. 
Additionally, all improvements were maintained 
during long-term follow-up. Preserved functional 
results and improved voiding parameters are the 
principal findings of our present study, and cons-
titute clinical proof of the utility of HoLEP. We 
strongly believe that the improvements that we 
recorded in various parameters reflect real clinical 
benefits of HoLEP.
Gupta et al. compared minimally invasive 
treatment options for symptomatic BPH soon af-
ter HoLEP was introduced (23). The cited authors 
emphasised that HoLEP afforded an ideal com-
bination of cutting and coagulation; however, a 
surgical learning curve was evident (23). Thus, 
HoLEP needs long learning curve according to our 
clinical experience. Additionally, we think that at 
least 20 cases should be performed in view of ex-
perienced surgeon on HoLEP.
Although surgical devices and skills have 
improved greatly, certain complications can no-
netheless develop after HoLEP. In our series, eight 
patients (8.3%) required re-operations; three be-
cause of residual adenomas, three to treat urethral 
strictures, and two to remove residual prostate tis-
sue in the bladder. Gilling et al. found that the 
long-term outcomes after HoLEP were at least as 
good as those after TURP, which had been consi-
dered to be the gold standard endoscopic treat-
ment option for BPH. Few complications (inclu-
ding re-operations) were noted in a study with 61 
patients (24). Yin et al. performed a meta-analysis 
and noted that HoLEP afforded better results than 
TURP, with minimal complications (4). Our findin-
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gs are similar to those summarised above. Shah 
et al. described the perioperative complications 
of HoLEP (25). Capsular perforation, superficial 
bladder mucosal injury, and injury to the ureteric 
orifice may be more prevalent when HoLEP rather 
than TURP is employed (25). We recorded two su-
perficial injuries to the bladder mucosa, but no other 
complications. Superficial coagulation stopped the 
bleeding. Two patients were followed-up via routine 
cystoscopy, because they had bladder tumours. Only 
one patient required a blood transfusion. Two pa-
tients were using anticoagulants, and, because of the 
intrinsic nature of laser treatment, they were allowed 
to continue their medications. Krambeck et al. repor-
ted that HoLEP was safe for patients taking antico-
agulants (5). Our findings are similar. Only one of 
our patients experienced stress urinary incontinence 
after HoLEP. Naspro et al. reported that the conti-
nence rate was high after HoLEP (16). Krambeck et 
al. reported less than 5% incontinence in a series of 
1.000 patients (17). Our findings were similar (5, 24, 
25). In view of these, HoLEP is a safe procedure with 
acceptable complications and presents an acceptable 
continence rate.
Mucosal injury can occur due to entrapment 
during morcellation of prostate tissue. Thus, surge-
ons should be aware of this. Two patients experien-
ced mucosa injury during morcellation, in this se-
ries. Cornu et al. reported that the LumenisⓇ device 
may morcellate more rapidly than the Wolf device 
(26). Ritter et al. reviewed the two morcellation de-
vices in an ex-vivo model and reported limitations 
of these devices (27). We used both devices, and we 
agree with the findings summarised above (26, 27). 
Additionally, clinicians should be aware that mor-
cellators can malfunction; a problem with residual 
prostate tissue may arise. In the present study, only 
a patient needed an additional operation to treat 
residual adenoma in the bladder. However, despite 
the (few) complications, HoLEP is a very accepta-
ble minimally invasive mode of surgery when it is 
necessary to treat an enlarged prostate. No compli-
cation was life threatening.
The retrospective nature of our work and the 
low numbers of patients are limitations of the study. 
However, the long-term follow-up with QoL scores, 
and the fact that this is the first patient series from 
Turkey, are useful features of the present study.
Our principal goals were to document im-
provements in voiding parameters and QoL, and 
an acceptable level of manageable complications, 
upon extended follow-up of 96 patients who un-
derwent HoLEP. Although the authors changed 
their workplaces during the follow-up time, I.A. 
was able to collect all long-term follow-up data 
because his new workplace is located in the city 
where the study was conducted. To the best of our 
knowledge, this is the first study to measure long-
-term QoL after HoLEP.
CONCLUSIONS
HoLEP is safe and effective when used to 
treat symptomatic BPH patients. Improvements in 
IPSSs, Qmax values, and PVR volumes prove that 
the long-term surgical outcomes are good. Reten-
tion of sexual function, an acceptable continence 
rate, and improvement in QoL, are major advanta-
ges of the procedure. Thus, HoLEP can be a viable 
option to TURP. Multi-institutional studies are ne-
eded to gather long-term post-HoLEP data.
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